Transanal total mesorectal excision (taTME) for rectal cancer: beyond the learning curve.
Anthony P D'AndreaElisabeth C McLemoreAntoinette BonaccorsoJordan M CuevasMotahar BasamAnna T TsayDeepika BhasinVikram AttaluriPatricia SyllaPublished in: Surgical endoscopy (2019)
Indications for taTME at experienced centers have expanded to include complex reoperative cases, local recurrences, metastatic cancer, and tumors with threatened CRM or IAS with evidence of post-treatment tumor regression. In the latter cases, taTME achieves good short-term outcomes and may facilitate R0 resection.